The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Journal
The breast journal
ISSN: 1524-4741
Titre abrégé: Breast J
Pays: United States
ID NLM: 9505539
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
02
2022
revised:
20
04
2022
accepted:
25
04
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
Breast cancer is a serious worldwide public health problem and is currently the most common cancer overall. Its endocrine therapy is related to the expression of the steroid hormones, estrogen receptor (ER), and progesterone receptor (PR). Breast cancers can be presented under multiple profiles of steroid hormones: ER(-)/PR(+), ER(+)/PR(-), double-positive/negative ER, and PR. 2-8% of all breast cancers express only PR (ER-/PR+) which is an abnormal phenotype, with less known about their behaviors and outcomes. Our study was performed on a large and well-characterized database of primary breast cancer from 2012 to 2019, up to 1159 cases. These cases were divided according to ER and PR expression, as we put all of our focus on ER-negative/PR-positive group, more specifically ER-/PR+/HER2+ and ER-/PR+/HER2- gene expressions, to highlight their features and find a pattern that links HR (hormone receptors) profiles and breast cancer subtypes. Out of the informative cases, 94 patients (8%) had ER-/PR+ breast cancers, while 676 (58.4%) had ER+/PR+, 88 (7.6%) had ER+/PR-, and 164 (14.2%) had ER-/PR- tumors. The ER-/PR+ group was statistically correlated with a high risk of recurrence and death in midway between the double-negative and double-positive HR. According to HER2 status, a low DFS was observed in patients ER-/PR+/HER2-, which is closer to the DFS of TNBC cases but worse than ER+/PR any. On the other side, the ER-/PR+/HER2+ showed also a poorer DFS closer to the HER2+ subgroup in between TNBC and ER+/PR any. The clinicopathological features of the ER-/PR+/HER2- and ER-/PR+ HER2+ have distinguished the patients into two groups with a difference in some clinicopathological characteristics: both groups had closer OS estimation, which was worse than ER-/PR any and better than TNBC and HER2. The ER-/PR+/HER2- seems to increase the risk of recurrence than ER-/PR+/HER2+ when compared to ER+/PR any. On the other hand, the ER-/PR+/HER2+ seems to increase the risk of death more than ER-/PR+/HER2- in comparison with ER+/PR any. Our results support that ER-/PR+ tumors really exist and are rare and clinically and biologically distinct subtypes of breast cancer. In addition, our analysis, which was based on dividing the groups according to HER2 expression, has revealed the existence of two distinct groups; this gave the ER-/PR+ subgroup a heterogeneity characterization. Moreover, this breast cancer subtype should not be treated as a luminal tumor but rather according to the HER2 expression status.
Identifiants
pubmed: 35711896
doi: 10.1155/2022/9238804
pmc: PMC9187286
doi:
Substances chimiques
Biomarkers, Tumor
0
Estrogens
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Progesterone
4G7DS2Q64Y
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9238804Informations de copyright
Copyright © 2022 S. Gamrani et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Am J Clin Pathol. 2005 Jan;123(1):21-7
pubmed: 15762276
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
PLoS One. 2015 Jul 10;10(7):e0132449
pubmed: 26161666
Arch Pathol Lab Med. 2010 Jun;134(6):907-22
pubmed: 20524868
BMC Cancer. 2015 Mar 18;15:138
pubmed: 25880075
Adv Anat Pathol. 2011 Jul;18(4):255-67
pubmed: 21654357
J Clin Oncol. 2008 Jan 10;26(2):335-6; author reply 336-8
pubmed: 18182677
Biol Res. 2017 Oct 2;50(1):33
pubmed: 28969709
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Breast. 2017 Aug;34 Suppl 1:S19-S26
pubmed: 28687441
Endocrinology. 1978 Nov;103(5):1742-51
pubmed: 748014
Pathol Oncol Res. 2011 Sep;17(3):663-8
pubmed: 21267685
Breast Cancer. 2016 Mar;23(2):310-7
pubmed: 25380989
J Clin Oncol. 2007 Oct 20;25(30):4772-8
pubmed: 17876012
Cancer Treat Rev. 2018 Jun;67:78-87
pubmed: 29772460
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
J Clin Oncol. 2005 Oct 20;23(30):7721-35
pubmed: 16234531
J Clin Oncol. 2001 Jan 1;19(1):18-27
pubmed: 11134191
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Lancet. 1998 May 16;351(9114):1451-67
pubmed: 9605801
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
Am J Pathol. 2017 Oct;187(10):2152-2162
pubmed: 28733194
JAMA Netw Open. 2020 Jan 3;3(1):e1918160
pubmed: 31899528
J Clin Pathol. 2017 Apr;70(4):320-326
pubmed: 27612503